Development of byom-1022 for the treatment of hyperemesis gravidarum-induced anxiety, depression and suicidal tendencies
Active Project Grant Awarded Last action
- Award ID
- HT9425261E228
- Recipient
-
Byomass Inc. UEI N57BMT7GFJG6
- Awarding agency
-
Defense Health Agency
Department of Defense
- Obligated
- $3,044,064
Award facts
- Assistance listing
- 12.420 Military Medical Research and Development
- Completion date 10% complete
- Place of performance
- Sudbury, MA 01776, USA
Award details come from USAspending.gov.
About this award
The Defense Health Agency awarded Byomass Inc. $3,044,064 on June 15, 2026, under the Military Medical Research and Development program (CFDA 12.420) to fund preclinical and clinical development of BYOM-1022, a novel therapeutic candidate for anxiety, depression, and suicidal ideation associated with hyperemesis gravidarum. The work is performed in Sudbury, Massachusetts, with a period of performance extending from the award date through June 14, 2030. Byomass is a for-profit biomedical research organization specializing in antibody development and small-molecule drug discovery for oncology and psychiatric therapeutic indications. The company receives this award as a prime recipient with no federal subcontracting relationships.
Quick answers
Who received award HT9425261E228?
HT9425261E228 was awarded to Byomass Inc. by Defense Health Agency (Department of Defense) on June 15, 2026.
How much is award HT9425261E228 worth?
$3,044,064 has been obligated on HT9425261E228.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award